These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 34212073)

  • 1. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.
    Alzhrani R; Alsaab HO; Vanamal K; Bhise K; Tatiparti K; Barari A; Sau S; Iyer AK
    Adv Ther (Weinh); 2021 Jun; 4(6):. PubMed ID: 34212073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer.
    Ostios-Garcia L; Villamayor J; Garcia-Lorenzo E; Vinal D; Feliu J
    World J Gastroenterol; 2021 Oct; 27(40):6775-6793. PubMed ID: 34790007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook.
    Tran LC; Özdemir BC; Berger MD
    Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Neither Hot nor Cold.
    Rubin SJS; Sojwal RS; Gubatan J; Rogalla S
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors.
    Yamada T; Tateishi R; Iwai M; Tanaka M; Ijichi H; Sano M; Koike K; Todo T
    Mol Ther Oncolytics; 2023 Mar; 28():31-43. PubMed ID: 36619294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights.
    Balsano R; Zanuso V; Pirozzi A; Rimassa L; Bozzarelli S
    Curr Oncol; 2023 Mar; 30(4):3871-3885. PubMed ID: 37185406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Pancreatic Ductal Adenocarcinoma Treatment.
    Anderson EM; Thomassian S; Gong J; Hendifar A; Osipov A
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?
    Narayanan S; Vicent S; Ponz-Sarvisé M
    Front Cell Dev Biol; 2021; 9():787249. PubMed ID: 34957115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma.
    Kaplon H
    Front Oncol; 2022; 12():835502. PubMed ID: 35664786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions.
    Tan E; El-Rayes B
    J Gastrointest Cancer; 2019 Mar; 50(1):1-8. PubMed ID: 30446922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.
    Muller M; Haghnejad V; Schaefer M; Gauchotte G; Caron B; Peyrin-Biroulet L; Bronowicki JP; Neuzillet C; Lopez A
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
    Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
    ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.
    Herting CJ; Karpovsky I; Lesinski GB
    Cancer Metastasis Rev; 2021 Sep; 40(3):675-689. PubMed ID: 34591240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic Tumor Microenvironment.
    Wang K; He H
    Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote the immunotherapy of pancreatic cancer.
    Wang R; Hong K; Zhang Q; Cao J; Huang T; Xiao Z; Wang Y; Shuai X
    Acta Biomater; 2023 Oct; 169():451-463. PubMed ID: 37572982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.